Ocular and Systemic Effects of Intravitreal Dexamethasone Sustained Release Implant in Refractory Diabetic Macular Edema

Abstract Purpose Intravitreal therapies with anti-VEGF medications are regarded as effective treatment option. The biodegradable intravitreal implant, Ozurdex (Allergan, Irvine, CA, USA) depends on slow-release dexamethasone. The present study aimed to assess the safety of intravitreal Ozurdex in patients with refractory DME. Methods This prospective study included patient with resistant DME who received intravitreal Ozurdex. baseline clinical evaluation, change in best corrected visual acuity BCVA and central retinal thickness CRT were analysed, intra ocular pressure, HbA1c, adverse effects were recorded. Results The reported CRT measurements showed significant decrease in the first 3 months post injection. The reported BCV showing significant improvement from the baseline values, there was significant increase in IOP in the first month only which was controlled with medical treatment, with no influence on HbA1c. Conclusions for patients with refractory macular oedema, Ozudex implant showed improvement in visual acuity and decreased macular thickness and there was no influence on metabolic control, side effects such as increase of intraocular pressure may require medical treatment.